Comparison Chart Arcus Biosciences, Inc.

Stocks

RCUS

US03969F1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 13:48:24 2026-08-27 EDT			5-day change	1st Jan Change
30.68 ^USD	-0.28%		+3.86%	+28.66%

08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	ARCUS BIOSCIENCES, INC.	Other Biotechnology & Medical Research	-0.28%	+3.86%	+28.66%	+190.34%	+3.86%	3.92B